Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Franklin Bright

Franklin Bright

University of Iowa Carver College of Medicine, USA

Title: Optimization of a nuclease-activated non-invasive optical imaging approach for S. aureus infections

Biography

Biography: Franklin Bright

Abstract

We previously described a novel molecular imaging technology capable of rapidly detecting S. aureus infections in mice. This was accomplished with an activatable near infrared (NIR) fluorescent probe consisting of a Cy5.5 fluorophore and a quencher attached to opposite ends of a synthetic oligonucleotide (RNA) sequence which is selectively cleaved by a secreted nuclease of S. aureus. Intravenous administration of this probe enabled the rapid detection of S. aureus infections in mouse thighs with non-invasive imaging. We are currently optimizing this approach for clinical applicability. This includes generating and testing probes with longer-wavelength fluorophores (i.e., that absorb and emit light of >750 nanometers). Near infrared wavelengths of >750 nanometers are known to penetrate tissues to a much greater extent than the ~700 nanometer light required to image the Cy5.5 fluorophore and could thus enable deeper imaging of tissues. However, the ability to robustly quench such “800 nm” fluorophores in vivo (a valuable endpoint for this optimization) has not been developed. Here, we will describe second generation quenched near-infrared fluorescent probes that include 800 nm fluorophores in place of Cy5.5. Quenching and nuclease-mediated activation were observed in vitro in buffer and in anticoagulated blood. Preliminary data indicate fluorescence increases at S. aureus infection sites and sites of nuclease injection in mice. Efforts to thoroughly characterize these probes in vivo, including in an S. aureus subcutaneous catheter biofilm infection model are ongoing.